Abstract:BACKGROUND The ARTISTIC (A Randomised Trial In Screening To Improve Cytology) trial originally reported after two rounds of primary cervical screening with human papillomavirus (HPV). Extended follow-up of the randomised trial cohort through a third round could provide valuable insight into the duration of protection of a negative HPV test, which could allow extended screening intervals. If HPV primary screening is to be considered in the national programme, then determining its cost-effectiveness is key, and a detailed economic analysis using ARTISTIC data is needed. AIMS/OBJECTIVES (1) To determine the round 3 and cumulative rates of cervical intraepithelial neoplasia (CIN) grade 2 or worse (2+) and CIN grade 3 or worse (CIN3+) between the revealed and concealed arms of ARTISTIC after three screening rounds over 6 years. (2) To compare the cumulative incidence of CIN2+ over three screening rounds following negative screening cytology with that following negative baseline HPV. (3) To determine whether or not HPV screening could safely extend the screening interval from 3 to 6 years. (4) To study the potential clinical utility of an increased cut-off of 2 relative light unit/mean control (RLU/Co) for Hybrid Capture 2 (HC2) and HPV genotyping in primary cervical screening. (5) To determine the potential impact of HPV vaccination with Cervarix™ in terms of preventing abnormal cytology and CIN2+. (6) To determine the cost-effectiveness of HPV primary screening compared with current practice using cervical cytology in England. DESIGN The ARTISTIC study cohort was recalled for a third round of screening 3 years after round 2 and 6 years following their enrolment to the study. Both arms of the original trial used a single protocol during round 3. SETTING ARTISTIC study cohort undergoing cervical screening in primary care in Greater Manchester, UK. PARTICIPANTS Between July 2007 and September 2009, 8873 women participated in round 3; 6337 had been screened in round 2 and 2536 had not been screened since round 1. INTERVENTIONS All women underwent liquid-based cytology and HPV testing and genotyping. Colposcopy was offered to women with moderate dyskaryosis or worse and with HPV-positive mild dyskaryosis/borderline changes. Women with negative cytology or HPV-negative mild dyskaryosis/borderline changes were returned to routine recall. MAIN OUTCOME MEASURES Principal outcomes were cumulative rates of CIN2+ over three screening rounds by cytology and HPV status at entry; HPV type specific rates of CIN2+; effect of age on outcomes correlated with cytology and HPV status; comparison of HC2 cut-off RLU/Co of both 1 and 2; and cost-effectiveness of HPV primary screening. RESULTS The median duration of follow-up was 72.7 months in round 3. Over the three screening rounds, there was no significant difference in CIN2+ [odds ratio (OR): 1.06, 95% confidence interval (CI) 0.89 to 1.26, p = 0.5)] or CIN3+ (OR: 0.90, 95% CI 0.72 to 1.14, p = 0.4) rates between the trial arms (revealed vs. concealed). Overall, 16% of women were HC2 positive at entry, decreasing from 40% in women aged 20-24 years to around 7% in women aged over 50 years. Abnormal cytology rates at entry were 13% for borderline+ and 2% for moderate+ cytology. Following positive cytology at entry, the cumulative rate of CIN2+ was 20.5%, and was 20.1% following a HPV-positive result at baseline. The cumulative CIN2+ rate for women who were HPV negative at baseline was only 0.87% (95% CI 0.70% to 1.06%) after three rounds of screening, significantly lower than that for women with negative cytology, which was 1.41% (95% CI 1.19% to 1.65%). Women who were HPV negative at baseline had similar protection from CIN2+ after 6 years as women who were cytology negative at baseline after 3 years. Women who were HPV positive/cytology negative at baseline had a cumulative CIN2+ rate at 6 years of 7.7%, significantly higher than that for women who were cytology positive/HPV negative (3.2%). Women who were HPV type 16 positive at baseline had a cumulative CIN2+ rate over three rounds of 43.6% compared with 20.1% for any HPV-positive test. Using a HC2 cut-off of RLU/Co ≥ 2 would maintain acceptable sensitivity and result in 16% fewer HPV-positive results. Typing data suggested that around 55-60% of high-grade cytology and CIN2+, but less than 25% of low-grade cytology, would be prevented by HPV vaccine given current rates of coverage in the UK national programme. For the cost-effectiveness analysis, most of the primary HPV strategies examined where HPV was used as the sole primary test were cost saving in both unvaccinated and vaccinated cohorts under baseline cost assumptions, with a 7-18% reduction in annual screening-associated costs in unvaccinated cohorts and a 9-22% reduction for vaccinated cohorts. Utilising partial genotyping at the primary screening stage to identify women with HPV 16/18 and referring them to colposcopy was the most effective strategy (barring co-testing, which is significantly more costly than any other strategies considered), resulting in 83 additional life-years per 100,000 women for unvaccinated women when compared with current practice, and similar life-years saved compared with current practice for vaccinated women. In unvaccinated cohorts, however, this genotyping strategy is predicted to result in a 20% increase in the number of colposcopies performed in England, although in vaccinated cohorts the number of colposcopy referrals was predicted to be lower than in current practice. For all strategies in which HPV is used as the sole primary screening test, decreasing the follow-up interval for intermediate-risk women from 24 to 12 months increased the overall effectiveness of primary HPV screening. In exploratory analysis, strategies for which cytology screening was retained until either age 30 or 35 years, and for which HPV testing was used at older ages, were predicted to be of higher costs and intermediate effectiveness than those associated with full implementation of primary HPV screening from age 25 years. However, this finding should be interpreted with caution as it depends on assumptions made about screening behaviour and compliance with recommendations at the 'switch over' point. CONCLUSIONS HPV testing as an initial screen was significantly more protective over three rounds (6 years) than the current practice of cytology and the use of primary HPV screening could allow a safe lengthening of the screening interval. A substantial decrease in high-grade cytology and CIN2+ can be expected as a consequence of the HPV vaccination programme. A HC2 cut-off of 2RLU/Co instead of the manufacturer's recommended cut-off of 1 would be clinically beneficial in terms of an optimal balance between sensitivity and specificity. Modelled analysis predicts that primary HPV screening would be both more effective and cost saving compared with current practice with cervical cytology for a number of potential strategies in both unvaccinated and vaccinated cohorts. Compliance with surveillance and optimal management of HPV-positive/cytology-negative women after primary HPV screening is of key importance. Limitations of the economic investigation included the need to make assumptions around compliance with screening attendance and follow-up for longer screening intervals in the future, assumptions regarding maintenance of current uptake vaccination in the future, and assumptions regarding the stability of cost of HPV and cytology tests in the future. Detailed sensitivity analysis across a range of possible assumptions was conducted to address these issues. This study and the economic evaluation lend support to convert from cytology to HPV-based screening. Future work should include researching (i) the attitudes of women who test HPV positive/cytology negative, (ii) the value of complementary biomarkers and (iii) activities relevant to primary HPV screening in unvaccinated and vaccinated populations from the point of view of QALY assessment. STUDY REGISTRATION Current Controlled Trials ISRCTN25417821.

Abstract:End stage renal disease (ESRD) is defined as treatment of renal dysfunction dependent on maintenance renal replacement therapy. It is estimated that the number of ESRD patients is about one million in China and is still fast growing. Patients with chronic kidney diseases are susceptible to cardiovascular disease because impaired glomerular filtration rate contributes independently to atherosclerosis in addition to the other usual risk factors. For patients of ESRD, cardiovascular disease is the leading cause of death, accounting for about 50% of mortalities.1 With the increasing prevalence of ESRD, more and more patients dependent on renal replacement therapy will need intervention, either surgical or catheter-based, for coronary artery disease. With regard to surgical revascularization, such patients undoubtedly have higher procedure-related mortality and morbidity. However, numerous worldwide centres have confirmed that good outcome can still be achieved through meticulous perioperative management. Interestingly, similar reports from China are very scant, with each containing few cases mixed with nondialysis patients. We published successful cardiovascular operations for dialysis patients from China.2 Here, we present the results of isolated coronary artery bypass grafting (CABG) surgery in patients dependent on maintenance dialysis at our institution. METHODS Between December 2004 and April 2011, five consecutive patients (three men and two women) dependent on maintenance dialysis underwent isolated coronary bypass grafting at Peking Union Medical College Hospital. The median age of these patients was 59 years (51 to 65). The causes of renal failure were diabetic nephropathy in four patients and chronic glomerolonephritis in one patient. Median preoperative duration of dialysis was 15 months (9 to 28 months). There were three patients on hemodialysis and two patients on peritoneal dialysis. At the time of operation, left ventricular function was normal in all patients and New York Heart Association status was II in three and III in two patients. The timing of operation was urgent in one patient due to intractable angina pectoris following failed percutaneous coronary intervention and elective in the other four patients. Preoperative patient characteristics are summarized in Table 1.Table 1: Preoperative data of patientsAll patients underwent coronary artery bypass surgery through standard midline sternotomy and with use of cardiopulmonary bypass (CPB). Proactive use of intra-aortic balloon pump was initiated before induction of anaesthesia for the case of urgent operation. Left internal mammary artery and saphenous vein (harvested via endoscopy) were used for all patients. After systemic heparinization, conventional CPB was instituted via two-stage cannulation in the right atrium and arterial perfusion through ascending aorta. Cardiac arrest was achieved through initial antegrade administration of high potassium cold blood cardioplegia, followed by intermittent retrograde perfusion. Patients were cooled to systemic temperature of 30°C to 32°C. After the grafts were anastomosed with target coronary arteries and ascending aorta, the aortic crossclamp was removed and CPB weaned after rewarming. Protamine was administrated according to the heparin dosage. All patients received dialysis as usual 12 to 24 hours prior to surgery and intraoperative hyperfiltration during CPB. Bedside continuous venovenous haemofiltration was routinely started on the first postoperative day, or later without presence of hyperkalaemia or volume overload. RESULTS There were three distal anastomoses in three patients and four in two patients (Tables 2 and 3). New onset of atrial fibrillation was observed in three of five patients and was converted to sinus rhythm with amidarone. One patient underwent re-exploration due to mediastinal bleeding 76 hours after the operation. The location of bleeding was found to be a stump of thin communicating artery in the bed of left internal mammary artery. For the patient requiring urgent operation, intraaortic balloon pump was discontinued 20 hours after the operation.Table 2: Operative variablesTable 3: Details of postoperative and follow-up characteristicsPatients were ventilated for 36 to 92 hours after the operation. Previous fashion of dialysis was resumed on the 5th to 7th postoperative day. Total volume of transfusion varied from 900 ml to 1600 ml. Moderate ileus was observed in one patient and was successfully managed by conservative treatment. One patient suffered transient cognitive disorder. No wound complication was seen. All patients were discharged (9th to 16th postoperative day) and were systemically followed up for 20 to 96 months. One of two patients previously on peritoneal dialysis switched to hemodialysis 14 months later due to peritonitis. At the end of the follow-up, all patients were in NYHA functional class II, free of angina pectoris and presented no major adverse cardiovascular events. No late death occurred. Computed tomographic angiogram was used to evaluate graft patency at 12 months and 36 months after the operation. All mammary grafts were patent, but one and three venous grafts were found to be occluded at 12 and 36 months respectively. DISCUSSION An optimal approach for coronary revascularization in the setting of ESRD remains undetermined. ESRD patients usually exhibit diffuse and severe atherosclerotic lesions of both coronary and peripheral arteries. Both surgical and interventional coronary revascularization treatment confront technical challenges. Previous studies suggest surgical revascularization conveys survival advantages over percutaneous coronary intervention. However, these patients usually have comorbidities predisposing them to increased operative morbidity and mortality. Documented in-hospital mortality of conventional CABG ranges between 3.4% to 25% in ESRD patients, which is roughly threefold to fivefold higher than nonESRD patients.3 Moreover, mortality was reported to have negative correlation with case volume. Although we have small number of cases, our ESRD patients undergoing isolated CABG exhibited good early and late outcomes. We believe that the key factors to success are adequate diameter of target coronary arteries and meticulous perioperative management. In addition, our perseverance in use of internal mammary artery also has substantial contribution, because previous studies have proven it to be protective against early and late death when compared with venous grafts in patients of impaired renal function.4 Off-pump CABG has become another appealing option for ESRD patients. Many studies reported off-pump CABG is associated with lower rates of mortality and morbidity in dialysis dependent patients. Without using CPB, off-pump CABG results in smaller volume shifts, less blood loss and less production of inflammatory mediators. Consequently, patients benefit from less cognitive disorders, shorter ICU stay and less transfusion. On the other hand, coronary arteries tend to be more diffusely calcified compared to the patients without ESRD, making off-pump surgical revascularization much more technically demanding. Therefore the possibility of incomplete revascularization might increase in ERSD patients if off-pump technique is used. This may subsequently undermine the survival advantage of surgical revasculerization. In a study published by Dewey et al,5 it was confirmed that patients had fewer bypass grafts and worse long-term survival after off-pump CABG than did patients undergoing on-pump CABG. We believe that success of off-pump coronary surgery in dialysis dependent patients can only be achieved by experienced surgeons and stringent patient selection. None of our patients was assigned to off-pump technique because their lesions were deemed as unsuitable for complete revascularization on a beating heart. In conclusion, surgical revascularization was successfully performed under cardiopulmonary bypass in five ESRD patients, early and late outcomes are good. Our experience suggests that CABG is a safe and effective procedure for ERSD patients.

GeMCRIS and Gene Transfer Product Characterization Vocabulary Development

Postoperative Outcomes After Gastrointestinal Surgery in Patients Receiving Chronic Kidney Replacement Therapy: A Population-based Cohort Study

The HK/MBD questionnaire: factor structure and discriminant validity with an adolescent sample.

Abdominal surgery in patients with chronic noncirrhotic extra hepatic portal vein obstruction: A multicenter retrospective study

Discussion with the feasibility of accepting surgery and the periopreative management in patients with maintenance dialysis.

Patient with chronic renal failure undergoing surgery

Clinical analysis of laparoscopic cholecystectomy in patients undergoing hemodialysis

Surgery and Chronic Kidney Disease

Cardiac surgery in end stage renal disease patients

Coronary artery bypass grafting in patients on maintenance dialysis: Is peritoneal dialysis a risk factor of operative mortality?

Open Heart Surgery in Patients with Chronic Renal Disease

Giant peptic ulcers in patients undergoing maintenance hemodialysis

Surgical Risk Assessment in Patients with Chronic Liver Diseases

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

Impacts of previous abdominal or pelvic surgery on peritoneal dialysis catheter’s placement in patients with end-stage renal diseases

Feasibility of the surgery unrelated to peritoneal dialysis in peritoneal dialysis patients

Aggressive surgical strategy should be used for the treatment of thoracic aortic disease in patients with end-stage renal disease

End-Stage Kidney Disease After Partial and Radical Nephrectomy Among Patients With Severe Chronic Kidney Disease

[Peri-operative management and follow-up outcomes of cardiac surgery in dialysis-dependent patients with end stage renal disease].

Endoscopic Approaches to the Treatment of Variceal Hemorrhage in Hemodialysis-Dependent Patients.

Coronary Bypass Grafting in Chinese Patients Dependent on Maintenance Dialysis.